PD1 inhibitor treatment for hepatocellular carcinoma should pay attention to the use of medication under doctor’s guidance, adopt the use of intravenous infusion to give medication, the use of intravenous infusion to give medication; intraoperative speed should not be too fast, can not be paired with dextrose solution and so on. Patients with advanced liver cancer who cannot be operated, especially those with hepatocellular carcinoma who have undergone at least one kind of systemic treatment, can be treated with PD1 inhibitors,, common drugs include bevacizumab, atilizumab, teraplizumab and so on. When treating, attention should be paid to monitoring the related side effects and handling them accordingly. Take atilizumab as an example. 1. Administer the drug by intravenous infusion, the recommended dose is 200 mg, once every 3 weeks. 2. The first infusion should last no less than 60 minutes; if well tolerated, each subsequent infusion should last no less than 30 minutes; 3. Do not administer by intravenous push or single rapid intravenous injection; 4. It is recommended that the solution be prepared immediately after removal from the refrigerator and that the diluted solution be used immediately; the diluted solution may be stored for no more than 24 hours. In addition, attention should be paid to observe whether adverse reactions occur, mainly immune-related adverse reactions (pneumonia, diarrhea and colitis, hepatitis, nephritis, etc.). For patients with suspected or confirmed liver cancer, it is recommended to go to regular hospitals to evaluate their condition and follow the doctor’s instructions to avoid delay. Please strictly follow the doctor’s instructions for drug treatment, and do not self-medicate or change the regimen.